The Trump Administration's Latest Drug Pricing Initiatives
By Tom Bulleit, Deborah Gardner, Kirsten Mayer and Scott Falin (January 14, 2019, 3:38 PM EST) -- Donald Trump's election in 2016 placed pharmaceutical companies in uncharted territory. Unlike predecessors from both major political parties, Trump did not shy away from directly criticizing the industry. Whether better seen as creating, or capitalizing on, widespread dissatisfaction with drug prices, President-elect Trump claimed that pharmaceutical companies were "getting away with murder" and promised to take action upon entering office. He went so far as to support the highly controversial idea of allowing the federal government to directly negotiate drug prices with the manufacturers....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.